Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Systematic Review of Second-Generation Flt3 Inhibitors for Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia Publisher



Mohebbi A1 ; Shahriyary F2 ; Farrokhi V1 ; Bandar B3, 4 ; Saki N3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Hematology and Blood Transfusion, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Hematology and Blood Transfusion, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Medical Laboratory, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  4. 4. Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Source: Leukemia Research Published:2024


Abstract

Background: Acute myeloid leukemia (AML) is a complex disease with diverse mutations, including prevalent mutations in the FMS-like receptor tyrosine kinase 3 (FLT3) gene that lead to poor prognosis. Recent advancements have introduced FLT3 inhibitors that have improved outcomes for FLT3-mutated AML patients, however, questions remain on their application in complex conditions such as relapsed/refractory (R/R) disease. Therefore, we aimed to evaluate the clinical effectiveness of second-generation FLT3 inhibitors in treating patients with R/R AML. Methods: A systematic literature search of PubMed, MEDLINE, SCOPUS and Google Scholar databases was made to identify relevant studies up to January 30, 2024. This study was conducted following the guidelines of the PRISMA. Results: The ADMIRAL trial revealed significantly improved overall survival and complete remission rates with gilteritinib compared to salvage chemotherapy, with manageable adverse effects. Ongoing research explores its potential in combination therapies, showing synergistic effects with venetoclax and promising outcomes in various clinical trials. The QuANTUM-R trial suggested longer overall survival with quizartinib compared to standard chemotherapy, although concerns were raised regarding trial design and cardiotoxicity. Ongoing research explores combination therapies involving quizartinib, such as doublet or triplet regimens with venetoclax, showing promising outcomes in FLT3-mutated AML patients. Conclusion: These targeted therapies offer promise for managing this subgroup of AML patients, but further research is needed to optimize their use. This study underscores the importance of personalized treatment based on genetic mutations in AML, paving the way for more effective and tailored approaches to combat the disease. © 2024 Elsevier Ltd
Related Docs
1. Identification of Furo[2,3-D]Pyrimidin-4-Ylsulfanyl-1,3,4-Thiadiazole Derivatives As Novel Flt3-Itd Inhibitors, European Journal of Medicinal Chemistry (2024)
2. Ultrasensitive Quantitation of Flt3-Itd Mutation in Patients With Acute Myeloid Leukemia Using Ddpcr, Molecular Biology Reports (2023)
Experts (# of related papers)
View all Related Experts
Alireza Foroumadi (1)
Seyed Esmaeil Sadat Ebrahimi (1)